Evaluation of Curcumin's effect on inflammation in hemodialysis patients.

Phase 2

• Conditions: End Stage Renal Disease.; End stage renal disease; N18.6

• Registration Number: IRCT20200613047751N1
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 July 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Interest to participate in the study
Suffering from chronic renal failure
Lack of consumption of nonsteroidal anti-inflammatory drugs
lack of consumption of Curcumin at least one month before study

Exclusion Criteria

Suffering from active cancer
History of cancer
Consumption of anti-coagulation drugs
Suffering of inflammatory and rheumatoid diseases
Suffering of active infection
History of bleeding through fistula
No consumption of 15 percent of tablets

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum's level of interleukin-6. Timepoint: Before intervention and 4 months after intervention. Method of measurement: ELISA test.;Erythrocyte sedimentation rate. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Modified Westergren.;Serum's level c- reactive protein. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Latex Agglutinasition.;Serum's level of ferritin. Timepoint: Before intervention and 4 months after intervention. Method of measurement: chemiluminescence.